Grant: Master's Award: Canada Graduate Scholarships
University of Toronto
$17,500.00
Investigating the role of glutamate in mitogen-activated protein kinase inhibitor-resistant melanoma and its effects on CD8+ T cell subsets and response to anti-PD1 immunotherapy
EF 2020-21
Résumé
Melanoma skin cancer is easily treatable on early detection, but less than half of patients with metastatic disease survive past two years. About 50% of melanoma patients have an alteration in the protein BRAF that increases cell growth and replication. These patients can be treated with BRAF inhibitors (BRAFi), but relapse occurs after 9-10 months. Relapse on BRAFi has been associated with tumour cells increasing export of glutamate, a molecule involved in cell metabolism. Glutamate can decrease the efficiency of T cells – warriors of the immune system that identify and kill invaders and cancer cells. Therefore, BRAFi may decrease the immune response to cancer. This is supported by evidence that patients treated with BRAFi become more resistant to subsequent immune checkpoint inhibitor therapy that increases immune response to cancer. It is therefore hypothesized that BRAFi increase tumour glutamate export which decreases effectiveness of immune therapy by lessening T cell killing ability. To test this, BRAFi-treated melanoma patients will be tested for increased tumour glutamate. Further investigation of glutamate effects will use mice. Mice will be injected with tumour cells that have increased, or normal, glutamate export and will be given immune checkpoint inhibitor treatment. If glutamate decreases immune system efficiency, mice with increased glutamate export will have less tumour shrinkage compared to those with normal glutamate export. Finally, to test the role of T cells, glutamate will be given to mouse T cells to assess changes in killing efficiency as measured by cell metabolism and proteins/signals given off by the cells. This result is important for improved treatment of many cancers as glutamate export is a common indicator of metastatic disease.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
449743
Name
Kates Meghan
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Investigating the role of glutamate in mitogen-activated protein kinase inhibitor-resistant melanoma and its effects on CD8+ T cell subsets and response to anti-PD1 immunotherapy
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Braf; Cancer Therapy Resistance; Cd8+ T Cells; Immunotherapy; Melanoma; Tc1; Tc17; Xct Transporter
Abstract
Melanoma skin cancer is easily treatable on early detection, but less than half of patients with metastatic disease survive past two years. About 50% of melanoma patients have an alteration in the protein BRAF that increases cell growth and replication. These patients can be treated with BRAF inhibitors (BRAFi), but relapse occurs after 9-10 months. Relapse on BRAFi has been associated with tumour cells increasing export of glutamate, a molecule involved in cell metabolism. Glutamate can decrease the efficiency of T cells – warriors of the immune system that identify and kill invaders and cancer cells. Therefore, BRAFi may decrease the immune response to cancer. This is supported by evidence that patients treated with BRAFi become more resistant to subsequent immune checkpoint inhibitor therapy that increases immune response to cancer. It is therefore hypothesized that BRAFi increase tumour glutamate export which decreases effectiveness of immune therapy by lessening T cell killing ability. To test this, BRAFi-treated melanoma patients will be tested for increased tumour glutamate. Further investigation of glutamate effects will use mice. Mice will be injected with tumour cells that have increased, or normal, glutamate export and will be given immune checkpoint inhibitor treatment. If glutamate decreases immune system efficiency, mice with increased glutamate export will have less tumour shrinkage compared to those with normal glutamate export. Finally, to test the role of T cells, glutamate will be given to mouse T cells to assess changes in killing efficiency as measured by cell metabolism and proteins/signals given off by the cells. This result is important for improved treatment of many cancers as glutamate export is a common indicator of metastatic disease.
Competitiondate
202012
Approvedterm2
1 yr 0 mth
Pinamesdelim
Kates, Meghan
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~